AU2022426690A1 - Covariate correction for temporal data from phenotype measurements for different drug usage patterns - Google Patents
Covariate correction for temporal data from phenotype measurements for different drug usage patterns Download PDFInfo
- Publication number
- AU2022426690A1 AU2022426690A1 AU2022426690A AU2022426690A AU2022426690A1 AU 2022426690 A1 AU2022426690 A1 AU 2022426690A1 AU 2022426690 A AU2022426690 A AU 2022426690A AU 2022426690 A AU2022426690 A AU 2022426690A AU 2022426690 A1 AU2022426690 A1 AU 2022426690A1
- Authority
- AU
- Australia
- Prior art keywords
- drug
- phenotype
- time points
- covariate
- computer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/40—Population genetics; Linkage disequilibrium
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/10—Boolean models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Chemical & Material Sciences (AREA)
- Theoretical Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Data Mining & Analysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Databases & Information Systems (AREA)
- Primary Health Care (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Physiology (AREA)
- Software Systems (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Pathology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Ecology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163294816P | 2021-12-29 | 2021-12-29 | |
| US202163294828P | 2021-12-29 | 2021-12-29 | |
| US202163294827P | 2021-12-29 | 2021-12-29 | |
| US202163294820P | 2021-12-29 | 2021-12-29 | |
| US202163294813P | 2021-12-29 | 2021-12-29 | |
| US202163294830P | 2021-12-29 | 2021-12-29 | |
| US63/294,827 | 2021-12-29 | ||
| US63/294,813 | 2021-12-29 | ||
| US63/294,820 | 2021-12-29 | ||
| US63/294,830 | 2021-12-29 | ||
| US63/294,828 | 2021-12-29 | ||
| US63/294,816 | 2021-12-29 | ||
| US202263351317P | 2022-06-10 | 2022-06-10 | |
| US202263351299P | 2022-06-10 | 2022-06-10 | |
| US202263351283P | 2022-06-10 | 2022-06-10 | |
| US63/351,299 | 2022-06-10 | ||
| US63/351,283 | 2022-06-10 | ||
| US63/351,317 | 2022-06-10 | ||
| US17/968,766 US20230207132A1 (en) | 2021-12-29 | 2022-10-18 | Covariate correction including drug use from temporal data |
| US17/968,766 | 2022-10-18 | ||
| PCT/US2022/054196 WO2023129622A1 (en) | 2021-12-29 | 2022-12-28 | Covariate correction for temporal data from phenotype measurements for different drug usage patterns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022426690A1 true AU2022426690A1 (en) | 2024-07-04 |
Family
ID=86896998
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022426690A Pending AU2022426690A1 (en) | 2021-12-29 | 2022-12-28 | Covariate correction for temporal data from phenotype measurements for different drug usage patterns |
| AU2022429829A Pending AU2022429829A1 (en) | 2021-12-29 | 2022-12-28 | Rare variant polygenic risk scores |
| AU2022425376A Pending AU2022425376A1 (en) | 2021-12-29 | 2022-12-28 | Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022429829A Pending AU2022429829A1 (en) | 2021-12-29 | 2022-12-28 | Rare variant polygenic risk scores |
| AU2022425376A Pending AU2022425376A1 (en) | 2021-12-29 | 2022-12-28 | Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20230207132A1 (cg-RX-API-DMAC7.html) |
| EP (5) | EP4457829B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2025502816A (cg-RX-API-DMAC7.html) |
| KR (3) | KR20240124391A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118451511A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2022426690A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3242597A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120977385B (zh) * | 2025-10-20 | 2026-02-06 | 浙江博圣生物技术股份有限公司 | 一种单基因遗传病致病突变的打分排序方法及系统 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1301633A1 (en) * | 2000-07-21 | 2003-04-16 | Althea Technologies, Inc. | A systematic approach to mechanism-of-response analyses |
| WO2014110350A2 (en) * | 2013-01-11 | 2014-07-17 | Oslo Universitetssykehus Hf | Systems and methods for identifying polymorphisms |
| CN111161799B (zh) * | 2019-12-24 | 2023-12-15 | 大连海事大学 | 一种基于多组学数据获取多基因风险评分的方法及系统 |
| WO2022020444A1 (en) * | 2020-07-22 | 2022-01-27 | Algen Biotechnologies, Inc. | Methods and systems for determining drug effectiveness |
-
2022
- 2022-10-18 US US17/968,766 patent/US20230207132A1/en active Pending
- 2022-10-18 US US17/968,723 patent/US20230207052A1/en active Pending
- 2022-10-18 US US17/968,285 patent/US20230207067A1/en active Pending
- 2022-12-28 KR KR1020247024939A patent/KR20240124391A/ko active Pending
- 2022-12-28 CA CA3242597A patent/CA3242597A1/en active Pending
- 2022-12-28 KR KR1020247024938A patent/KR20240124390A/ko active Pending
- 2022-12-28 CN CN202280086064.0A patent/CN118451511A/zh active Pending
- 2022-12-28 JP JP2024539696A patent/JP2025502816A/ja active Pending
- 2022-12-28 JP JP2024539698A patent/JP2025502818A/ja active Pending
- 2022-12-28 KR KR1020247025104A patent/KR20240131385A/ko active Pending
- 2022-12-28 EP EP22854644.6A patent/EP4457829B1/en active Active
- 2022-12-28 CN CN202280086055.1A patent/CN118475982A/zh active Pending
- 2022-12-28 EP EP22854643.8A patent/EP4457819A1/en active Pending
- 2022-12-28 CN CN202280086049.6A patent/CN118451506A/zh active Pending
- 2022-12-28 EP EP25226976.6A patent/EP4742250A3/en active Pending
- 2022-12-28 CA CA3242710A patent/CA3242710A1/en active Pending
- 2022-12-28 EP EP22854642.0A patent/EP4457818B1/en active Active
- 2022-12-28 AU AU2022426690A patent/AU2022426690A1/en active Pending
- 2022-12-28 AU AU2022429829A patent/AU2022429829A1/en active Pending
- 2022-12-28 AU AU2022425376A patent/AU2022425376A1/en active Pending
- 2022-12-28 JP JP2024539697A patent/JP2025502817A/ja active Pending
- 2022-12-28 EP EP26156124.5A patent/EP4715828A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4457829C0 (en) | 2026-02-04 |
| CN118451511A (zh) | 2024-08-06 |
| EP4715828A2 (en) | 2026-03-25 |
| EP4457829B1 (en) | 2026-02-04 |
| US20230207052A1 (en) | 2023-06-29 |
| US20230207067A1 (en) | 2023-06-29 |
| KR20240131385A (ko) | 2024-08-30 |
| CN118451506A (zh) | 2024-08-06 |
| EP4457819A1 (en) | 2024-11-06 |
| KR20240124391A (ko) | 2024-08-16 |
| CN118475982A (zh) | 2024-08-09 |
| EP4742250A2 (en) | 2026-05-13 |
| EP4457818B1 (en) | 2025-12-24 |
| EP4457818C0 (en) | 2025-12-24 |
| JP2025502818A (ja) | 2025-01-28 |
| CA3242597A1 (en) | 2025-02-26 |
| JP2025502816A (ja) | 2025-01-28 |
| US20230207132A1 (en) | 2023-06-29 |
| JP2025502817A (ja) | 2025-01-28 |
| AU2022429829A1 (en) | 2024-07-04 |
| EP4457818A1 (en) | 2024-11-06 |
| EP4457829A1 (en) | 2024-11-06 |
| EP4715828A3 (en) | 2026-06-17 |
| AU2022425376A1 (en) | 2024-06-27 |
| KR20240124390A (ko) | 2024-08-16 |
| CA3242710A1 (en) | 2023-07-06 |
| EP4742250A3 (en) | 2026-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023129621A1 (en) | Rare variant polygenic risk scores | |
| EP4413575A1 (en) | Combined and transfer learning of a variant pathogenicity predictor using gapped and non-gapped protein samples | |
| US20250201348A1 (en) | Artificial intelligence-based detection of gene conservation and expression preservation at base resolution | |
| US20250218534A1 (en) | Artificial intelligence-based epigenetics at base resolution | |
| EP4457829B1 (en) | Covariate correction for temporal data from phenotype measurements for different drug usage patterns | |
| US20240112751A1 (en) | Copy number variation (cnv) breakpoint detection | |
| US20230343413A1 (en) | Protein structure-based protein language models | |
| US20230108368A1 (en) | Combined and transfer learning of a variant pathogenicity predictor using gapped and non-gapped protein samples | |
| WO2023129622A1 (en) | Covariate correction for temporal data from phenotype measurements for different drug usage patterns | |
| WO2023129619A1 (en) | Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers | |
| Mohammed et al. | Enhancing Hypertrophic Cardiomyopathy Heart Risk Assessment with Deep Learning and Multi-Omics Data Integration | |
| WO2023059750A1 (en) | Combined and transfer learning of a variant pathogenicity predictor using gapped and non-gapped protein samples | |
| Nahlawi | Increasing the Discovery Power and Confidence Levels of Disease Association Studies: A Survey | |
| CN119920308A (zh) | 一种预测细胞系特异功能性非编码变异的方法 |